3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Completed
2
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
6
Esophageal Squamous Cell Carcinoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Medulloblastoma
1
Locally Advanced Rectal Carcinoma
1
High-Risk Cancer
1
Fallopian Tube Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Breast Cancer Metastatic
1
Breast Cancer Invasive
1
Interventions
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Bevacizumab
3
oregovomab
2
Nivolumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cisplatin
2
tislelizumab
1
spartalizumab
1
rucaparib
1
olaparib
1
niraparib
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
denileukin diftitox
1
anlotinib
1
Surveys and Questionnaires
1
Saline Solution
1
Ramucirumab
1
Platinum
1
Nutrition Assessment
1
Neoadjuvant Therapy
1
Leucovorin
1
Irinotecan
1
Immunotherapy, Adoptive
1
Glucose
1
Gemcitabine
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Ovarian Epithelial
×
Neoadjuvant Therapy
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled